Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes

Sarina Levy-Mendelovich, Nitzan Atia,Ivan Budnik,Assaf Arie Barg,Einat Avishai,Omri Cohen,Tami Brutman-Barazani,Tami Livnat,Gili Kenet

Research and Practice in Thrombosis and Haemostasis（2023）

Cited 0|Views25

No score

Abstract

•Data regarding maintenance of immune tolerance in patients treated with emicizumab are scarce.•Patients with hemophilia A and FVIII inhibitors who initiated emicizumab were followed up for 3 years.•No inhibitor recurrence was noted among fully tolerized patients.•Successfully tolerized patients with hemophilia A treated with emicizumab did not lose tolerance.

Translated text

Key words

viii,emicizumab,inhibitors

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined